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BACKGROUND & AIMS: Cirrhosis and chronic inflammation
precede development of hepatocellular carcinoma (HCC) in
approximately 80% of cases. We investigated immune-related
gene expression patterns in liver tissues surrounding early-
stage HCCs and chemopreventive agents that might alter these
patterns to prevent liver tumorigenesis. METHODS: We
analyzed gene expression profiles of nontumor liver tissues from
392 patients with early-stage HCC (training set, N ¼ 167 and
validation set, N ¼ 225) and liver tissue from patients with
cirrhosis without HCC (N ¼ 216, controls) to identify changes in
expression of genes that regulate the immune response that
could contribute to hepatocarcinogenesis. We defined 172 genes
as markers for this deregulated immune response, which we
called the immune-mediated cancer field (ICF). We analyzed the
expression data of liver tissues from 216 patients with cirrhosis
without HCC and investigated the association between this gene
expression signature and development of HCC and outcomes of
patients (median follow-up, 10 years). Human liver tissues were
also analyzed by histology. C57BL/6J mice were given a single
injection of diethylnitrosamine (DEN) followed by weekly doses
of carbon tetrachloride to induce liver fibrosis and tumorigen-
esis. Mice were then orally given the multiple tyrosine inhibitor
nintedanib or vehicle (controls); liver tissues were collected and
histology, transcriptome, and protein analyses were performed.
We also analyzed transcriptomes of liver tissues collected from
mice on a choline-deficient high-fat diet, which developed
chronic liver inflammation and tumors, orally given aspirin and
clopidogrel or the anti-inflammatory agent sulindac vs mice on a
chow (control) diet. RESULTS: We found the ICF gene expres-
sion pattern in 50% of liver tissues from patients with cirrhosis
without HCC and in 60% of nontumor liver tissues from pa-
tients with early-stage HCC. The liver tissues with the ICF gene
expression pattern had 3 different features: increased numbers
of effector T cells; increased expression of genes that suppress
the immune response and activation of transforming growth
factor b signaling; or expression of genes that promote
inflammation and activation of interferon gamma signaling.
Patients with cirrhosis and liver tissues with theimmunosuppressive profile (10% of cases) had a higher risk of
HCC (hazard ratio, 2.41; 95% confidence interval, 1.21–4.80).
Mice with chemically induced fibrosis or diet-induced steato-
hepatitis given nintedanib or aspirin and clopidogrel down-
regulated the ICF gene expression pattern in liver and devel-
oped fewer and smaller tumors than mice given vehicle. CON-
CLUSIONS: We identified an immune-related gene expression
pattern in liver tissues of patients with early-stage HCC, called
the ICF, that is associated with risk of HCC development in
patients with cirrhosis. Administration of nintedanib or aspirin
and clopidogrel to mice with chronic liver inflammation caused
loss of this gene expression pattern and development of fewer
and smaller liver tumors. Agents that alter immune regulatory
gene expression patterns associated with carcinogenesis might
be tested as chemopreventive agents in patients with cirrhosis.Keywords: Cancer; Microenvironment; Cytokines; Lymphocytes.
iver cancer is the fourth leading cause of cancer-
1Lrelated mortality worldwide. Hepatocellular carci-
noma (HCC) accounts for more than 90% of liver cancers
and is the main cause of death in patients with cirrhosis.2,3
HCC arises from chronic liver inflammation, fibrosis, and
eventually cirrhosis in 70%–80% of cases.2 In developed
countries, curative treatments are feasible in 30%–40% of
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
We investigated inflammatory and immune-related gene
expression patterns in liver tissues surrounding early-
stage HCCs and chemopreventive agents that might
alter these patterns to prevent liver tumorigenesis.
NEW FINDINGS
We identified a gene signature that associated with risk of
HCC development in patients with cirrhosis.
Administration of immunomodulatory and anti-
angiogenic agents to mice with chronic inflammation
and fibrosis reduced this gene expression pattern and
reduced development of liver tumors.
LIMITATIONS
This was a retrospective analysis of human liver tissue
samples and the chemopreventive agents were tested in
mice with liver tumors due to chronic fibrosis or
steatosis. More human studies are needed.
IMPACT
This gene expression signature might be used to identify
patients with cirrhosis who are at risk for HCC.
Pharmacologic agents that alter this gene expression
pattern might be tested in chemoprevention studies.




LIVERcases, but recurrence is high, and no effective adjuvant
therapies are available.2,4 In addition, in approximately
40%–50% of patients, diagnosis is made at advanced stages,
when currently approved molecular therapies yield limited
survival benefits (approximately 1 year).3 Despite recent
advances in the management and clearance of hepatits C
virus (HCV) infection, there is an unmet need for early
detection and application of chemopreventive approaches in
patients at high risk for HCC development.
To date, there are no established preventive strategies for
HCC in patients at risk beyond prevention with antiviral
therapies.5 Once cirrhosis is established, antiviral therapies
reduce but do not eliminate the risk of HCC.4,6,7 Individual risk
assessment is a key first step in the successful development of
any chemopreventive strategy. In this regard, increasing evi-
dence suggests the existence of the so-called cancerfield effect
or field cancerization, which consists of predisposing onco-
genic and inflammatory signals occurring during chronic liver
injury and ultimately leading tomalignant transformation.8–10
Gene signatures derived from the cirrhotic tissue adjacent to
HCC tumors have been designed to predict poor outcome,
particularly in patients with cirrhosis and HCV infection who
are at higher risk of HCC development.9,11–14 Overall, these
studies support the feasibility of usingmolecular scores of the
carcinogenic field to identify patients at high risk for HCC
development. However, the carcinogenic roles of inflamma-
tion and immune response in the context offield cancerization
have been poorly explored. Understanding the immune fea-
tures governing the unresolved cancerfield effect is crucial for
identifying potential therapeutic targets in patients at high
risk for HCC development.
In this study, the analysis of the inflammatory milieu
that characterizes the underlying liver disease in whichHCC tumors arise has led to the identification of an
immune-mediated cancer field (ICF) in 60% of patients with
early HCC and 50% of patients with cirrhosis but without
HCC. This ICF comprises 3 distinct molecular subtypes: the
high-infiltrate ICF subtype, with increased infiltration of
effector T cells; the immunosuppressive ICF subtype, with
activation of stroma and transforming growth factor (TGF) b
signaling; and the proinflammatory ICF subtype, with up-
regulation of interferon (IFN) gamma signaling. These im-
mune profiles, particularly the immunosuppressive cancer
field, predict increased risk of HCC development in cirrhotic
patients. Inhibition of this carcinogenic field significantly
reduced HCC onset in 2 mouse models of chronic liver
damage and hepatocarcinogenesis. Overall, our study pro-
vides the rationale for exploring chemopreventive strategies
in patients with cirrhosis at high risk for HCC development.
Materials and Methods
Human Cohort
Gene expression data from a cohort of 167 surgically resec-
ted fresh-frozen samples (Heptromic data set, GSE63898) with
matched tumor and adjacent nontumor tissue were analyzed.
Samples were previously collected (1998–2008) in the setting of
the HCC Genomic Consortium after institutional review board
approval. Full descriptions of the cohort and RNA profiling data
are available in previous publications.15,16 Supplementary
Table 1 provides a summary of the clinicopathologic variables
of the samples used in the current study (training cohort,
N¼ 167). Validation of the identifiedmolecular profiles was then
performed in an independent set of 225 adjacent nontumor liver
tissues previously characterized by our group (GSE10143).9
Finally, to identify those patients without neoplasm at higher
risk of HCC development and most likely to benefit from
chemopreventive strategies, our findings were evaluated in a
previously characterized cohort of patients with early cirrhosis
(N ¼ 216, GSE15654)14 and a publicly available data set of
fibrotic liver tissues (N ¼ 124, GSE84044).17
Modeling the Immune-Mediated Cancer Field
Enrichment scores of 4872 gene sets that represent cell
states and perturbations of the immune system (collection C7
of MSigDB, Broad Institute)18 were calculated by single-sample
gene set enrichment analysis (ssGSEA) in the nontumor liver
tissue of the training cohort. Next, unsupervised clustering
analysis by the nonnegative matrix factorization19 method was
performed to identify the presence of an ICF. To characterize
the samples presenting an ICF and to identify different ICF
subtypes, a second unsupervised clustering was performed
with ssGSEA scores obtained for a curated set of gene signa-
tures representative of individual cell types,20,21 cancer
immune-related signaling pathways,22 and inflammation- or
immune-specific biological processes (Hallmark collection of
MSigDB, Broad Institute).
Generation of an Immune-Mediated Field Gene
Signature
An ICF field gene signature was generated by using the top
differentially expressed genes in each molecular group (false
















discover rate,<0.05; fold-change 2) and was then validated in
an independent data set with nearest template prediction
analysis (P < .05) (Gene Pattern modules).23
Molecular Characterization of the Immune-
Mediated Cancer Field Subtypes and
Identification of Candidate Therapies
To characterize the ICF subtypes, gene expression signa-
tures (available in MSigDB [Broad Institute] or previously re-
ported [Supplementary Table 2]) were assessed by GSEA,
ssGSEA, nearest template prediction, and ingenuity pathway
analyses. CIBERSORT20 was used to estimate the relative frac-
tion of 22 immune cell types within the leukocyte compartment
of nontumor liver tissues. The immunophenoscore algorithm24
was used to analyze the major immunogenic determinants. An
in silico analysis based on ssGSEA scores of approximately
1230 gene sets (DSigDB) recapitulating targets of approved
therapies was also performed for the screening of candidate
targeted therapies.
Histologic Evaluation of Infiltrating Inflammation
Histopathologic analysis was performed in 98 of 167 cases.
Specifically, H&E staining of formalin-fixed, paraffin-embedded
tissue section of HCCs and their matched adjacent nontumor
livers were evaluated by 2 expert pathologists (Carla Montironi
and Manel Sole). The presence of inflammation (portal/septal,
interface, pericentral, and lobular) as well as the lymphoid
aggregates were assessed in the nontumor liver tissue sections.
More details on the histologic evaluation of the samples have
been included in Supplementary Material.
Animal Models
We generated a chemically induced model of HCC and
fibrosis in male C57BL/6J mice (Harlan Laboratories, N ¼ 55)
by a single injection of diethylnitrosamine (DEN) followed by
weekly dosing with carbon tetrachloride (CCl4), as previously
described.25 Once fibrosis was established, mice were randomly
assigned to receive vehicle or nintedanib (50 mg/kg;
Boehringer Ingelheim, Rhein, Germany). Mice were killed at
different time points, and liver and tumor tissue samples were
collected and processed for histologic, transcriptomic, and
protein expression analyses (see Supplementary Material). All
experimental procedures were carried out with the approval of
the institutional ethical committee of the University of Barce-
lona and Hospital Clinic of Barcelona. Additionally, liver
samples of a choline-deficient high-fat diet (CD-HFD)–fed
mouse model reported in a recent study26 were collected. A
total of 25 samples were processed for transcriptomic profiling,
including mice fed a chow diet (n ¼ 5) or CD-HFD for
12 months and given vehicle (n ¼ 4), aspirin/clopidogrel
(n ¼ 6), or sulindac (n ¼ 10).
Statistical Analysis
All analyses were performed with SPSS software, version 23
(IBM, Armonk, NY) or GraphPad (San Diego, CA) Prism, version
5.00. Correlations for categorical and continuous variables
were analyzed by Fisher exact test and Wilcoxon rank-sum test,
respectively. The prognostic value of the signatures was
assessed with Kaplan-Meier estimates, log-rank test, and Coxregression models. In in vivo studies, the Mann-Whitney U test
was used to compare differences in body weights, liver func-
tion, tumor number, tumor size, and CD4/CD8-stained area in
human samples. The Fisher exact test was performed for
analysis of HCC incidence and phosphorylated extracellular
signal-regulated kinase (pERK) staining. The Student t test was
used to compare the differences in Sirius Red quantification,
CD31 staining, CD4/CD8 staining proportion of immune cell
infiltrate in mice, and relative gene expression.Transcript Profiling
Gene Expression Omnibus accession numbers are from
previously deposited data from our group (GSE63898,
GSE10143, GSE15654) and others (GSE84044). Newly profiled
mice samples are in the Gene Expression Omnibus under
accession number GSE125975 and GSE133969.Results
Identification of a Novel Immune-Mediated
Cancer Field Effect in Nontumor Liver Tissue of
Patients With Early Hepatocellular Carcinoma
To characterize the immune features governing the un-
resolved cancer field in which new cancers arise,
transcriptome-based analysis of a compendium of approxi-
mately 5000 annotated immunology-specific gene sets18
was performed in the nontumor liver tissue of patients
with early-stage HCC. This analysis showed the presence of
an ICF in approximately 60% (98/167) of samples
(Figure 1A and Supplementary Figure 1). Specifically, these
samples were characterized by enrichment of several gene
sets recapitulating the presence of activated immune cells,
as well as up-regulation of core signaling pathways involved
in immune response (both innate and adaptive) and those
involved in the modulation of inflammatory response (ie,
interleukin [IL] 2–signal transducer and activator of tran-
scription [STAT] 5, IL-6/STAT3, IL-17, IFN gamma, colony-
stimulating factor, tumor necrosis factor [TNF] a, and
TGF-b signaling) (Figure 1A and B and Supplementary
Figure 1). Moreover, histologic evaluation confirmed that
liver tissues with ICF contained a higher frequency of
moderate to marked inflammatory infiltrate (74% in ICF vs
52% in non-ICF, P¼ .034) and lymphoid aggregates (80% in
ICF vs 55% in non-ICF, P ¼ .009) (Figure 1C and D and
Supplementary Table 3). Immunostaining for CD4þ and
CD8þ further confirmed significantly higher levels of T-cell
infiltrates in the adjacent livers of patients with the ICF
(Supplementary Figure 2A). In contrast, histologic evalua-
tion of the tumor showed no significant correlation between
presence of the ICF and detection of intratumoral or peri-
tumoral infiltration (Supplementary Table 3). This is in
accordance with our recent publication,15 where the tumor
immune-based profile did not correlate with the presence or
absence of immune gene signatures in the surrounding
nontumor tissue.
While characterizing the ICF we detected that, in addi-
tion to immunogenic features, several well-known carcino-
genic signals, such as epithelial-to-mesenchymal transition,




LIVERKRAS, epidermal growth factor receptor (EGFR), and
vascular endothelial growth factor (VEGF) signaling, were
also significantly enriched in liver tissues containing the ICFFigure 1. Identification of an ICF effect in nontumoral liver tissu
ICF present in 60% of patients with HCC. High and low ssGSEA
predicted upstream cytokine and transcription factors activated
degree of portal/septal infiltrating inflammation. Original mag
presence or absence of lymphoid aggregates. Original magnifi
nearest template prediction; PD-1, programmed cell death prot(Supplementary Table 4). In line with these oncogenic sig-
nals, a significant enrichment of previously reported prog-
nostic signatures derived from the adjacent nontumorale adjacent to early HCCs. (A) Heatmap representation of the
scores are represented in red and blue, respectively. (B) Top
in liver tissues of ICF patients. (C) Representative images of
nifications are given. (D) Representative images depicting
cations are given. HIR, hepatic injury and regeneration; NTP,
ein 1.
November 2019 Immune-Mediated Field Cancerization as Target for HCC Prevention 1387liver were also detected. These signatures included the
186-gene cancer-field signature,9 activated hepatic stellate
cells (HSCs),11 hepatic injury and regeneration,13 and mul-
ticentric occurrence of HCCs27 (Figure 1A). The presence of
the ICF significantly correlated with HCV infection; features
indicative of liver dysfunction such as high bilirubin, low
platelet count, and albumin levels (Supplementary Table 5);
and poor survival (median overall survival, 43.4 months
in the ICF group vs 94.8 months in the non-ICF group;
P ¼ .001], (Supplementary Table 6 and Supplementary
Figure 1B). Altogether, our data highlight the presence of
an ICF in 60% of patients with early HCC. This ICF is
characterized by activation of immunomodulatory signaling
cascades (ie, IFN-g, TNF-a, TGF-b, and IL-6), along with
cancer-promoting signaling pathways (ie, epithelial-
mesenchymal transition, EGFR, and vascular endothelial
growth factor receptor [VEGFR]), and is associated with















The Immune-Mediated Cancer Field Contains 3
Distinct Molecular Subtypes
Further dissection of the key immune-modulating
signaling pathways and immune-cell infiltrates in those
samples harboring the ICF showed the existence of 3
distinct molecular subtypes. The first molecular subtype, the
high-infiltrate ICF subtype (23% of the ICF), showed a sig-
nificant enrichment of several previously established gene
signatures mirroring the presence and/or activation of im-
mune cell infiltrates such as lymphocytes (T and B cells)22,28
or macrophages29 (Figure 2A and B). Consistently, immu-
nogenicity, herein captured either by the cytolytic activity
score (Figure 2A)30 or by using the immunophenoscore al-
gorithm24 (Figure 2B), was also significantly higher in these
samples (P < .001). Specifically, nontumor liver samples
belonging to the high-infiltrate ICF subtype showed signifi-
cant infiltration of effector T cells (Figure 2B) (P  .001),
including increased levels of cytotoxic CD8þ T cells assessed
both by transcriptomic (P ¼ .03) and immunohistochem-
istry (P ¼ .0002) (Figure 2C and Supplementary Figure 2B).
This subtype also was characterized by enrichment of the
previously reported ectopic lymphoid structures signa-
ture31 (Figure 2A). In addition, the high-infiltrate ICF was
significantly associated with poor survival compared with
the rest of the patients (Supplementary Figure 1C), although
there were no significant differences among the distinct ICF
subtypes (Supplementary Figure 1D). The second subtype,
the immunosuppressive ICF (36% of the ICF), was charac-
terized primarily by activation of stroma and HSCs,
increased TGF-b signaling, and T-cell exhaustion
(Figure 2A). Moreover, several immune checkpoints (ie,
CTLA-4, TIGIT, LAG3) were significantly overexpressed
(immunophenoscore, P < .01) in this class, along with
higher levels of M2 macrophages (P ¼ .04) and CD4þ
memory resting cells (P ¼ .005), which are among the main
mediators of immune tolerance and inhibition (Figure 2B
and C). The third subtype (41% of the ICF) showed a clear
predominance of IFN gamma signaling (P < .001)
and enrichment of the inflammatory M1 macrophages(P < .0001); it is called the proinflammatory ICF subtype
(Figure 2A–C). The high-infiltrate and immunosuppressive
subtypes shared several molecular features, including the
enrichment of key signaling pathways involved in
modulating the immune response (ie, IL-2 and TNF
signaling), proliferation (ie, KRAS signaling), and angiogen-
esis (P < .001) (Figure 2A).
To further confirm the presence and molecular traits of
the identified ICF, we generated a transcriptome-based gene
signature able to capture the 3 ICF subtypes. This signature
showed only minimal overlap (0%–5%) with previously
reported gene signatures of field cancerization in HCC
(Supplementary Figure 3).9,12,14,32 The resulting 172-gene
signature (Supplementary Table 7) was then validated in
the adjacent nontumor tissue of 225 patients with early
HCC, previously characterized by our group9,33
(Supplementary Figure 4A). Similar to what was previ-
ously observed in the training cohort, 58% (130/225) of
patients belonged to the ICF. Moreover, in this cohort, the
presence of the ICF was an independent predictor of poor
survival (hazard ratio, 2.73; 95% confidence interval [CI],
1.1–6.8; P ¼ .03) (Supplementary Figure 4B and
Supplementary Table 8). Within the ICF group, approxi-
mately 31% (40/130) presented the high-infiltrate ICF,
approximately 27% (35/130) the immunosuppressive ICF,
and approximately 42% (55/130) the proinflammatory ICF
subtype (Supplementary Figure 4A). Subsequent molecular
characterization further confirmed the ability of the
signature to capture the main molecular traits defining
each subtype, such as increased infiltration of effector T
cells in the high-infiltrate subtype, activation of stroma
and TGF-b signaling in the immunosuppressive subtype,
and up-regulation of IFN gamma signaling in the proin-
flammatory subtype (Supplementary Figure 4A). Overall,
our results highlight the presence of a poor prognosis-
related ICF comprising 3 molecular subtypes with a
high degree of lymphocyte infiltration (overall, 16% of
patients with HCC) or predominance of either immuno-
suppressive (overall, 20% of patients with HCC) or
proinflammatory (overall, 24% of patients with HCC)
signaling cascades.The Immune-Mediated Cancer Field, Particularly
the Immunosuppressive Subtype, Predicts a High
Risk of Hepatocellular Carcinoma Development
in Patients With Cirrhosis
After the identification of an ICF in the livers of 60% of
patients with early HCC, we next sought to assess its role in
liver disease progression and HCC primary occurrence.
To this end, the 172-gene signature was analyzed in a cohort
of 216 patients with nonmalignant cirrhosis with a median
follow-up of 10 years in the context of an HCC surveillance
program.14 Overall, 51% (110/216) of patients with
cirrhosis harbored the ICF, including the high-infiltrate ICF
subtype in 28% (31/110), the immunosuppressive
ICF subtype in 19% (21/110), and the proinflammatory ICF
subtype in 53% (58/110) of patients with cirrhosis
harboring the ICF.





Figure 3. Association of the presence of the immunnosup-
pressive ICF with HCC occurrence and prognostic variables
in patients with cirrhosis. (A) Kaplan-Meier estimates of
HCC development, (B) overall survival, and (C) hepatic
















Next, we tested the capacity of the ICF subtypes to
predict the risk of HCC development in patients with
cirrhosis. The presence of the immunosuppressive ICF
subtype (10% of all patients with cirrhosis) was signifi-
cantly associated with a higher risk of HCC development
(median time to HCC development of 7.4 years [95% CI, 3.2–
11.7] vs 17.1 years [95% CI, 10.6–23.7] in Rest, P < .0001]
and was found to be an independent predictor of HCC
occurrence in patients with cirrhosis in a multivariate
analysis (hazard ratio, 2.41; 95% CI, 1.2–4.8; P ¼ .012)
(Figure 3A and Table 1). In addition, the immunosuppres-
sive ICF was also significantly associated with poor survival
(median overall survival, 7.1 years [95% CI, 4.5–9.6] vs 16.3
years [95% CI, 9.1–23.5] in Rest; P < .0001) and higher risk
of hepatic decompensation (median time to hepatic
decompensation, 6.5 years [95% CI, 4.3–8.6] vs >15 years
in Rest; P< .0001) (Figure 3B and C). Patients with cirrhosis
harboring the high-infiltrate and proinflammatory ICF sub-
types also showed a nonsignificant trend toward a higher
risk of HCC development compared with those patients
lacking the ICF (mean time to HCC development, 12.8 years
[95% CI, 11.5–14.2] in other ICF subtypes vs 16.3 years
[95% CI, 14.2–18.5] in non ICF, P ¼ .06) (Supplementary
Figure 5A).
Moreover, the analysis of an additional cohort of 124
patients without neoplasia with liver fibrosis17 showed that
the ICF may occur as a progressive event because it was
significantly correlated with increasing levels of fibrosis
stage and degree of inflammation (Supplementary
Figure 5B). Particularly, the presence of the immunosup-
pressive ICF was significantly correlated with the presence
of advanced liver fibrosis (Scheuer fibrosis S3-4 score,17 P ¼
.034) (Supplementary Figure 5B).
In conclusion, the ICF detected in patients with early
HCC is also present in the livers of approximately 50% of
patients with cirrhosis and captures the presence of a
damaging and continuous inflammatory response in the
underlying liver disease. Furthermore, our results under-
score the critical role of an immunosuppressive ICF (overall,
10% of patients with cirrhosis) in defining a 2.4-times risk
of HCC development and, to a smaller extent, of the high-
infiltrate and proinflammatory subtypes.decompensation, according to the presence of the
immunosuppressive ICF subtype (orange).The Immune-Mediated Field as a Target for
Chemoprevention in a Mouse Model
Recapitulating Chronic Liver Inflammation and
Hepatocellular Carcinoma Development
Based on the compelling results described, we hy-
pothesized that the ICR, particularly the=
Figure 2. The ICF contains 3 distinct molecular subtypes. (A) H
nificance is highlighted. (B) Immunophenogram representing the
subtypes (C) Comparison of estimated proportion of immune c
senting those immune populations with estimated average
subtypes. Significant statistical differences observed among the
immunosuppressive, orange; proinflammatory, green; and both
.01, and ***P < .001. CP, checkpoint, EC, effector cell; MDSC, m
complex in antigen presenting cells; NTP, nearest template preimmunosuppressive ICF subtype, may represent an ideal
target for chemopreventive strategies in patients with
cirrhosis at high risk for HCC development. To this pur-
pose, an in silico–based analysis was performed with our
training cohort to identify those candidate therapies mosteatmap representation of the 3 ICF subtypes. Statistical sig-
enrichment of immunogenic determinants in the distinct ICF
ells (CIBERSORT method) between the ICF subtypes, repre-
fraction >5% and significant differences between the ICF
different ICF subtypes are highlighted (high infiltrate, purple;
high infiltrate and immunosuppressive, black). *P < .05, **P <
yeloid-derived suppressor cell; MHC, major histocompatibility
diction; SC, suppressor cells; Treg, regulatory T cell.
Table 1.Univariate and Multivariate Analysis of Risk of Hepatocellular Carcinoma Development in Patients With Cirrhosis




Multivariate analysis (Cox regression)
P value 95% CI P value
Nontumoral liver tissue–based transcriptomic profiles
lmmunosuppressive-lCF .03 2.41 1.21–4.80 .01





HCV genotype 1b .18
Alcohol consumption (>80 g/day) .68
HCV etiology plus alcohol consumption .68
History of antiviral treatment (IFN based) .65
Varices .02 1.49 0.85–2.6 .17
Spleen .13
lshak score of 6 vs 5 .24
Platelet count (<100,000/mm3) .02 1.51 0.91–2.64 .15
Bilirubin (>1 mg/dL) <.01 1.85 1.07–3.2 .03
Alpha-fetoprotein (>10 ng/mL) .87
Prothrombin time (international normalized ratio >1.2) .38
NOTE. Text in bold font indicates statistical significance.




LIVERlikely to modulate the identified ICF. This analysis was
based on the enrichment of a compendium of approxi-
mately 1230 gene sets (DSigDB collections D1 and D2)34
recapitulating the main targets of 1202 approved drugs.
Among the top 10 most significantly enriched drugs
(Supplementary Figure 6), nintedanib was the only ther-
apy approved by the US Food and Drug Administration
indicated for a noncancer condition. Specifically, ninteda-
nib is the first molecular targeted therapy with clinical
efficacy in patients with idiopathic pulmonary fibrosis as
both an anti-fibrogenic and anti-inflammatory agent.35
Given these considerations, the efficacy of nintedanib in
reverting the pro-tumorigenic ICF was tested in a mouse
model of HCC development in the setting of chronic
inflammation and liver fibrosis (Supplementary
Figure 7A). In this model, the macroscopic evaluation of
explanted livers in DEN/CCl4 mice killed at the ages of 15,
17, and 18 weeks confirmed the development of numerous
hepatic tumors (Figure 4A). Tumor penetrance and num-
ber of tumors progressively increased, ultimately reaching
a 100% incidence at 18 weeks of age (Figure 4A and B). At
all time points, histologic evaluation of the liver sections
showed that a portion of the tumors were preneoplastic
(dysplastic) nodules (Figure 4C). In mice killed at 15
weeks of age (Supplementary Figure 7A), nintedanib
showed a clear trend toward reducing HCC incidence,
number, and size of tumors (Figure 4B, D, and E). These
differences reached significance at 17 weeks of age
(Figure 4B), having a marked decrease in both overall
tumor burden (30% in nintedanib vs 89% in vehicle
group, P ¼ .019) and, specifically, in HCC incidence (7% vs
33%, P ¼ .04). Similarly, at 18 weeks of age, HCC incidencewas significantly reduced in treated mice (22% vs 77%, P
< .001) (Figure 4B). In addition, nintedanib significantly
reduced the overall tumor number and size both at 17 and
18 weeks of age (Figure 4D and E). Overall, nintedanib
was well tolerated with no significant induction of
body weight loss or hepatotoxicity measured by serum
alanine aminotransferase and aspartate aminotransferase
levels (Supplementary Figure 7B and C). Taken together,
our data suggest that nintedanib is safe and efficacious
in preventing HCC development in our experimental
model.Nintedanib Treatment Reverts the Immune-
Mediated Cancer Field Effect
Next, we sought to assess the impact of nintedanib
treatment on the ICF. For this purpose, we analyzed gene
expression profiling of nontumor liver samples from
17-week-old DEN/CCl4 mice given nintedanib (n ¼ 10) or
vehicle (n ¼ 9) and 3 healthy control mice. First, the com-
parison between the healthy control and vehicle groups
showed a profile of activated pathways compatible with
HCC development within a fibrotic and inflammatory
background. In this regard, functional analysis of differen-
tially expressed genes (Supplementary Table 9) highlighted
the activation of hepatic stellate cells and fibrogenesis, as
well as immune system activation (inflammatory response,
chemotaxis, binding of myeloid and leukocytes) in vehicle-
treated DEN/CCl4 livers (Supplementary Table 10).
Notably, our model presented a significant enrichment of
the gene set representing the ICF identified in humans
(P ¼ .001) and faithfully recapitulated the human ICF
Figure 4. Nintedanib reduces HCC onset in mice. (A) Representative pictures of macroscopic evaluation of hepatic tumors in
mice given vehicle or nintedanib and killed at 15, 17, and 18 weeks of age. Arrows indicate macroscopically visible tumors. (B)
Evaluation of overall tumor burden and HCC incidence. #Statistical significance for overall tumor burden. *Statistical signifi-
cance for HCC incidence. (C) Microscopic evaluation of the number of tumors per mouse in each group. (D) Number of
macroscopic tumors per mouse given vehicle or nintedanib at the different time points. (E) Diameter size of the largest tumor
per mouse given vehicle or nintedanib at the 3 different time points. # or *P < .05, ## or **P < .01, and ### or ***P < .001. Nin,
nintedanib; Veh, vehicle; w, weeks.





































subtypes described (Figure 5A). The comparison of the
gene expression profiles of adjacent nontumor liver
from mice treated with vehicle or nintedanib showed
that nintedanib significantly down-regulated the ICF sub-
types and, more specifically, the proinflammatory and
immunosuppressive ICF phenotypes, which predict risk of
HCC development in patients with cirrhosis (P ¼ .02)
(Figure 5A). A nonsignificant trend was also observed for
the high-infiltration subtype (Figure 5A). Treatment with
nintedanib led to a significant down-regulation of inflam-
matory cues (IL-6/STAT3, IFN alfa, and IFN gamma) and
immune-related signaling (IL-2/STAT5 activation, allograft
rejection) (Figure 5A). Among the infiltrating immune cells,
nintedanib significantly reduced the presence of B and
T cells, activated macrophages, helper T cells, and regula-
tory T cells along with associated immune modulators
(ie, IL1, CCL5, and PDL1) (Figure 5A). Despite exhibiting
similar global levels of inflammatory infiltrates, quantifi-
cation of CD4- and CD8-positive infiltrating lymphocytes
by immunohistochemistry showed a significant decrease
of CD4þ T cells in nintedanib-treated mice compared
with controls (P < .05) (Figure 5B).
Next, to further characterize the chemopreventive
effects of nintedanib, we assessed the activation status of
the main nintedanib targets (ie, VEGFR2 and platelet-
derived growth factor receptor b). Western blot of
nontumor liver tissue confirmed that nintedanib blocked
the activation of VEGFR2 (Figure 5C) and its downstream
effectors protein kinase B and ERK (Supplementary
Figure 8A). Consistently, both liver parenchyma and
liver tumors were pERK positive in vehicle-treated mice
and pERK negative in nintedanib-treated mice (P < .05)
(Supplementary Figure 8B), indicating an antiproliferative
effect of nintedanib as well. Given the strong inhibition of
VEGFR signaling observed, we next assessed the anti-
angiogenic effect of nintedanib in DEN/CCl4 mice. In this
model, reduced CD31 staining was associated with
diminished blood vessel area in both liver parenchyma
and liver tumors of nintedanib-treated mice (Figure 5D).
Together, these data suggest that nintedanib exhibits its
chemopreventive effects in part by inducing vascular
normalization and inhibiting hepatic proliferation. In
contrast, no reduction of fibrosis degree, the profibrogenic
signaling pathway platelet-derived growth factor
receptor b, or collagen markers were detected in the
livers of nintedanib-treated mice (Supplementary
Figure 8C–E).
Overall, our data confirm that therapeutic targeting of
the ICF, accompanied by liver vascular normalization and
suppression of hepatic proliferation, can prevent the=
Figure 5. Nintedanib and aspirin/clopidogrel reduce the ICF in a
(A) Heatmap representation of high and low ssGSEA scores for
subtypes. (B) Representative images and quantification of CD4þ
mice given vehicle (n ¼ 5) or nintedanib (n ¼ 5). (C) Western
renchyma of 17-week-old mice given vehicle (n ¼ 6) or nintedani
by CD31 immunostaining in 5 randomly selected, low-magnificat
Single sample GSEA analysis of the ICF signature in the differen
.001. AspClo, aspirin/clopidogrel; Nin., nintedanib; Sulin, sulinddevelopment of HCC associated with advanced chronic liver
disease.Immunomodulatory Effects of Aspirin/
Clopidogrel Treatment Revert the Immune-
Mediated Cancer Field Effect and Prevent
Hepatocarcinogenesis In Vivo
To further support the concept of an ICF in promoting
HCC development and its therapeutic immunomodulation
as a candidate strategy for chemoprevention, we per-
formed gene expression profiling in nontumor liver
derived from the recently described mouse model of CD-
HFD treated either with the immunomodulatory combi-
nation aspirin/clopidogrel or the anti-inflammatory
sulindac.26 Of particular interest, in this model, which
presents nonalcoholic fatty liver disease–related liver
inflammation with various degrees of fibrosis and HCC
development after 12 months of diet regimen,26,36,37 HCC
prevention was achieved only through the combination of
the anti-inflammatory drug, aspirin, and clopidogrel (an
P2Y12 inhibitor) (25% vs 0% 12-month HCC incidence,
control vs combination, respectively; P ¼ .01)26 and not
sulindac alone (25% vs 20% 12-month HCC incidence,
control vs sulindac, respectively; P ¼ not significant; data
not shown).
In the context of our study, comparative analysis be-
tween the nontumor liver of healthy control and CD-HFD
mice showed a significant enrichment of the ICF signa-
ture in CD-HFD mice (P ¼ .002) (Figure 5E). All 3 ICF
subtypes were significantly up-regulated in CD-HFD mice
compared with healthy controls (Figure 5E), along with the
enrichment of signaling pathways regulating inflammation
(ie, IL6/STAT3, TNF-a), immune infiltration and activa-
tion,22,28 and epithelial-to-mesenchymal transition (ie,
TGF-b) (P < .05). These data were consistent with the high
intrahepatic influx of metabolically activated CD8þ T cells
and natural killer (NK) cells (CD3þNK1.1þ) measured in
CD-HFD–fed mice by flow cytometry.26 Overall, these data
confirm the existence of an ICF in an independent model of
chronic liver disease, further suggesting a role in
hepatocarcinogenesis.
Next, we compared the expression profiles of liver
samples from CD-HFD vehicle-treated mice with CD-HFD
mice treated with the combination aspirin/clopidogrel
(n ¼ 6) or sulindac alone (n ¼ 10). Only aspirin/clopidogrel,
but not sulindac alone, was able to prevent HCC and revert
the ICF within the liver microenvironment (P ¼ .05),
with the proinflammatory ICF subtype being the most
significantly down-regulated upon treatment (Figure 5B).nimal models of chronic inflammation and HCC development.
the 172-gene signature and gene sets recapitulating the ICF
and CD8þ infiltrating lymphocytes in the livers of 17-week-old
blot analysis of VEGFR2 activation in the nontumor liver pa-
b (n ¼ 6). (D) Morphometric quantification of blood vessel area
ion fields in mice given vehicle (n ¼ 5) or nintedanib (n ¼ 5). (E)
t treatment arms of the CD-HFD model. **P < .01 and ***P <
ac; Veh., vehicle.




LIVERParticularly, based on previous molecular characteriza-
tion,26 the inhibition of the ICF seemed to be accompanied
by a significant reduction in the degree of liver damage and
a significantly reduced number of CD8þ and NK T cells in
the liver.
Overall, these data support the role of the ICF in pro-
moting carcinogenesis and suggest that only those drugs
able to simultaneously inhibit several components of the ICF
by targeting mitogenic, angiogenic, and immunomodulatory
kinases (ie, nintedanib and aspirin/clopidogrel) present a
more efficacious therapeutic index for HCC prevention.Discussion
This study represents an in-depth analysis of the in-
flammatory milieu associated with the field cancerization in
the chronically injured liver and investigates its clinical
implications for the prediction and prevention of HCC
occurrence in patients with cirrhosis.
The role of the cancer field effect in promoting
neoplastic transformation has gained much interest in
recent years, and currently an altered microenvironment is
considered a promoter of cancer.8,10 Although under phys-
iologic conditions inflammation is an adaptive response to
tissue injury, when the inflammatory stimuli persist, the
nonresolved inflammation contributes to carcinogen-
esis.38,39 Along these lines, activation of HSC and certain
pathways, such as nuclear factor kB and TGF-b signaling,
have been previously associated with liver fibrogenesis and,
eventually, neoplastic transformation.9,12 With this study,
we move beyond the limits of current knowledge and pro-
vide a detailed description of the immune microenviron-
ment underlying the field cancerization in the liver. To this
end, we first characterized the immune profile of the non-
tumor liver parenchyma of 392 early HCCs and then
investigated its role in predicting HCC development in 216
patients with cirrhosis having long-term surveillance for
HCC (median, 10 years).14 The analysis showed that up to
60% of HCCs and 50% of cirrhotic patients showed a
deleterious immune-mediated response in the surrounding
tissue, which was associated with impaired liver function,
activation of specific oncogenic loops, angiogenesis, and
poor survival. Further characterization identified 3 distinct
subtypes with different levels of lymphocyte infiltration and
activation of either immunosuppressive or proinflammatory
traits. In particular, the immunosuppressive ICF subtype
(approximately 10% of patients with cirrhosis) was an in-
dependent predictor of HCC development, increasing by 2.4
times the risk of cancer development, whereas both the
high-infiltrate and the proinflammatory subtypes showed a
trend toward higher risk of HCC occurrence in cirrhosis. The
identification of distinct immune subtypes reflects the
complex role of the immune system in hepatocarcino-
genesis, with both an activated immune response and an
exhausted immune microenvironment contributing to
create a pro-tumorigenic environment and increase the risk
of HCC development.40
Reducing the incidence and mortality of HCC requires
advances in chemopreventive approaches at preneoplasticstages, in addition to curative treatment options for early
lesions. Universal immunization against hepatitis B virus
and antiviral therapies against hepatitis B virus and HCV
have been associated with greatly reduced HCC risk.2,41,42
Once cirrhosis is established, the risk of HCC development
remains despite achievement of a sustained virologic
response in patients with HCV.6,7 In addition, the incidence
of other risk factors, such as nonalcoholic steatohepatitis, is
dramatically increasing.2 Thus, alternative HCC preventive
strategies capable of interfering with molecular hep-
atocarcinogenesis are an unmet need. Furthermore, identi-
fying those patients at high risk of HCC development should
enable a cost-effective selection of patients most likely to
benefit from chemopreventive approaches. In this scenario,
our results are of clinical relevance because the ICF, and
specifically the immunosuppressive subtype, may provide a
novel companion biomarker to enrich at-risk patients in
chemoprevention clinical trials. Given these observations,
we then sought to investigate whether the molecular forces
driving such cancer fields could serve as targets for che-
mopreventive strategies. Hence, we first verified that the
molecular profiles observed in human cirrhosis were faith-
fully reproduced in 2 animal models of chronic liver injury.
The DEN/CCl4 chemically induced mouse model and the
recently described nonalcoholic steatohepatitis/HCC
model26 reliably recapitulated the presence of a carcino-
genic phenotype observed in liver tissues from patients
belonging to the ICR.
To identify the most promising candidate therapies
for novel chemopreventive strategies, we conducted an
in silico analysis using a large compendium of gene
sets34 recapitulating the main targets of 1202 approved
drugs. Among the top 10 most significantly enriched
drugs, we selected nintedanib, the only therapy
approved by the US Food and Drug Administration for
non-neoplastic conditions. In the DEN/CCl4 animal
model, oral administration of nintedanib reduced the
ICF, including the immunosuppressive ICF subtype, ul-
timately reducing HCC incidence and growth. Reversion
of the ICF induced by treatment with nintedanib was
accompanied by reduction of CD4þ lymphocytes, which
could be due to its mechanism of action inhibiting the
src family of kinases (ie, LCK, FLT3, and SRC). These
findings are in line with previous reports suggesting
that CD4þ cells propagate immune-mediated liver injury
in models of chronic liver inflammation or autoimmune
liver disease.43,44 Pretreatment with T-cell–specific anti-
bodies or immunosuppressive agents, such as anti-CD4
monoclonal antibody, FK506 (tacrolimus), or cyclo-
sporine A, have been shown to ameliorate hepatitis in
these models, further supporting the role of CD4þ T cells
in inducing liver damage.43 Results in a second animal
model treated with the combination of the anti-
inflammatory drug, aspirin, and clopidogrel (a P2Y12
inhibitor) confirmed the therapeutic potential of immu-
nomodulating the ICF and supported the pro-tumorigenic
role exerted by the immune response. Indeed, only the
treatment able to modulate the ICF, as indicated by the
reduction of immune cells (ie, CD8þ and NK T cells) and
















the reversion of the ICF signature, successfully reduced
liver damage and prevented HCC development. Overall,
our study identifies a novel promising chemopreventive
strategy for HCC and confirms the validity of using the
reversion of the ICF as reliable readout of efficacy. This
is of great clinical importance because there is currently
no effective method to monitor the short-term effects of
chemopreventive drugs.5 Nintedanib belongs to a new
generation of tyrosine kinase inhibitors that, in addition
to exerting immune modulation, block the activation of
main angiogenic receptors.45 Many cytokines and growth
factors are involved in modulating the formation of new
vessels. Expression of VEGF and its receptors is elevated
in HCC cell lines and tissues, as well as in the blood
circulation of patients with HCC.33,46–48 In our model,
nintedanib exerted its chemopreventive mechanisms in
part through the inhibition of VEGF signaling, a major
driver of angiogenesis.49 Thus far, independent studies
had reported that HCC prevention can be achieved in
animal models by attenuating liver fibrosis through the
inhibition of EGFR50,51 or lysophosphatidic acid32
signaling. With the current study, we show that modu-
lation of the liver microenvironment by molecular tar-
geted drugs, which simultaneously block liver
inflammation and angiogenesis, might represent a
powerful alternative strategy.
We recently defined the immune class of HCC15 and the
immune exclusion class (characterized by active Wnt/
CTNNB1),3,15,52 which might predict response and primary
resistance to checkpoint inhibitors, respectively.3,52 Here,
we explored the immunomodulatory mechanisms under-
lying HCC occurrence by defining an immune-mediated
field effect that conforms to a cancer-permissive milieu,
thus placing these patients at the highest risk of HCC
development. In addition, our preclinical data with a drug
approved for pulmonology and non–small-cell lung cancer
treatment suggest that the permissive microenvironment
can be reverted, leading to a reduction in HCC occurrence.
These data provide the rationale for testing this strategy in
early chemoprevention trials targeting patients with
cirrhosis who are at high risk of HCC development. In
addition, this strategy could also be further explored in the
adjuvant setting considering that 60% of HCC undergoing
resection also present this permissive milieu in the adja-
cent nontumoral tissue.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at https://doi.org/10.1053/
j.gastro.2019.07.028.References
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Histologic Analysis of Human Samples
Histologic evaluation was performed in 98 tissue sam-
ples obtained from patients with early HCC included in the
study cohort. The portal/septal, pericentral, and lobular
inflammation were assessed as follows: 0, absent; 1, mild; 2,
moderate; and 3, marked. The presence or absence (1 or 0,
respectively) of interface inflammation and lymphoid ag-
gregates was also evaluated. The latter structures were
mainly found in the periportal/periseptal areas. An in-
flammatory infiltrate score was created by summing the
values given by the portal/septal, lobular, and interface
inflammation. Pericentral inflammation was not considered
for the scoring system because 57% of patients had
cirrhosis. According to the final score, we defined 2 in-
flammatory categories: the absent/mild category if the
score was <3 and the moderate/marked category if the
score was 3. The presence or absence of cirrhosis was
defined according to the METAVIR algorithm1 (F0-1-2-3/
F4). Ductular proliferation was also considered. Steatosis
was assessed based on the size of the fat vesicles (macro-
vesicular or microvesicular) and the localization of the fat
droplets in the liver parenchyma (periseptal/periportal,
pericentral, or lobular). The presence or absence of
ballooning, apoptotic bodies, and oncocytic change was also
evaluated. Immunohistochemistry for CD4 and CD8 was
performed in a subset of 70 patients of the training cohort.
Staining was carried out on 3-mm-thick formalin-fixed
paraffin-embedded tissue sections collected from a 40–
44C flotation bath containing deionized water and moun-
ted on 25  75 mm positively (þ) charged slides. The slides
were dried at 60C in a convection oven for 30 minutes.
Deparaffinization was performed, followed by standard cell
conditioning 1 (ULTRA CC1 from Ventana Medical Systems,
Tucson, AZ). Staining was performed with the Ventana
BenchMark ULTRA system with the primary antibody for
approximately 20 minutes at 36C. Signal was captured
using the Ultraview Universal diaminobenzidine detection
kit and blocked with antibody diluent (REF 251-018) for 8
minutes. Samples were counterstained with hematoxylin for
4 minutes and post-counterstained with Bluing Reagent for
4 minutes. The primary antibodies used were anti-CD4
(clone SP35; Roche, Basel, Switzerland) and anti-CD8
(clone SP57, Roche). The quantification was done auto-
matically (Image J, National Institutes of Health, Bethesda,
MD) by calculating the positive areas (mm2)—considering 5
random areas within the lobular and portal/septal in-
filtrates of the nontumor liver tissue—at 200 times
magnification and using the same threshold for all samples.
Generation of the Diethylnitrosamine/Carbon
Tetrachloride Animal Model
The chemically induced (DEN/CCl4) model was gener-
ated as previously described.2,3 HCC was induced by a
single intraperitoneal injection of DEN (Sigma-Aldrich, St.
Louis, MO; 25 mg/kg intraperitoneally, dissolved in 0.9%
sodium chloride solution) given at day 15 postpartum fol-
lowed by 11–14 weekly injections of CCl4 (0.5 mL/kg
intraperitoneally, dissolved in corn oil) starting at 4 weeks
of age (Supplementary Figure 7A). Mice (N ¼ 55) were
randomly assigned at 12 weeks of age to receive 50 mg/kg/
day of nintedanib (Boehringer Ingelheim) (n ¼ 29) or
vehicle (n ¼ 26). The vehicle solution was formulated as
follows: 1.8% hydroxypropyl b–cyclodextrin, 5% acetic acid
(10%), and Natrosol (0.5%) (Sigma-Aldrich (#54290), Saint
Louis, MO). At 15, 17, and 18 weeks of age, mice were killed
48 hours after the last dose of CCl4, having been treated with
nintedanib for 3, 5, and 6 weeks, respectively (n¼ 15–21 per
time point). Immediately after mice were killed, livers were
explanted, digitally photographed, and weighed. The evalu-
ation of macroscopic malignant nodules was assessed by
2 independent investigators. Based on visual criteria, a he-
patic lesion with a diameter >0.5 mm and with dysmorphic
and/or dyschromic surface was considered a hepatic tumor.
The diameter of tumors was measured with a hand caliper.
The biological endpoints for chemopreventive efficacy were
(1) incidence of hepatic tumors; (2) number of tumors;
and (3) size, considering the largest diameter of all counted
tumors. The largest liver lobe was fixed in buffered 4%
paraformaldehyde for 24 hours for posterior histologic
and immunohistochemical analysis. In addition, samples of
adjacent nontumor liver were snap frozen at –80C for
subsequent RNA and protein analysis. Potential treatment-
related toxicity was evaluated by monitoring body weight
losses and quantitative determination of serum aspartate
aminotransferase and alanine aminotransferase.
Histologic and Immunohistochemical Analysis of
the Mouse Samples
FFPE mouse liver samples were cut in 4-mm sections
and stained with H&E for further histologic examination.
The samples were assessed, with nontumor and tumor
tissue considered, by 2 expert liver pathologists (CM, MS)
blinded to the treatments. In the nontumor tissue, the
number of lymphoid aggregates was determined. These
were defined as polarized aggregates composed mainly of
lymphocytes with scant plasma cells, neutrophils, and
macrophages localized in the periportal and pericentral
areas with a measure no bigger than 0.1 mm. The presence
of inflammatory infiltrates was also determined for the
periportal, pericentral, and lobular areas using a scoring
system as follows: 0, absence or rare; 1, mild; 2, mild/
moderate; 3, moderate; 4, moderate/marked; and 5,
marked. Other variables, such as the presence of micro-
abscesses, ductular proliferation (0, absence; 1, <25% of
portal tracts involved; 2, 25%–50% of portal tracts
involved; 3, >50% of portal tracts involved), necrosis,
steatosis, and apoptotic bodies, were also determined.
Ballooning was defined according to the following scale: 0,
absence; 1, focal; 2, multiple foci; 3, diffuse. Hepatic fibrosis
was assessed by Sirius Red staining. The METAVIR algo-
rithm1 was used to grade hepatic fibrosis from F0 (no
scarring) to F4 (cirrhosis or severe fibrosis). Also, peri-
sinusoidal fibrosis was evaluated as follows: 1, 0%–5%; 2,
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5%–33%; 3, 33%–66%, and 4, >60%. Histologically, he-
patic tumors presented a high cellular density composed of
small cells with altered nuclear/cytoplasmic ratio and a
clear cytoplasm. Among these hepatic tumors, those that
were circular, well-defined lesions with pushing margins
were diagnosed as HCCs, whereas a dysplastic nodule was
considered when the lesion had an ill-defined shape within
the liver parenchyma. The presence of vascular invasion
was a characteristic attributed to HCC. The size of both le-
sions was not used to make a distinction between them,
although HCCs tend to be larger than dysplastic nodules.
Finally, for the evaluation of the chemopreventive effects of
a tyrosine kinase inhibitor in adjacent liver tissue, FFPE
sections from mice killed at 17 weeks of age were analyzed
by immunohistochemistry (n ¼ 5 mice per treatment arm).
Heat-induced antigen retrieval was performed with 10
mmol/L sodium citrate buffer (pH 6.0) or 0.5 mol/L Tris
buffer (pH 10.0) for 15 minutes (5 minutes, 3 times), and
the reaction was quenched using hydrogen peroxide 3%.
After washing with phosphate-buffered saline, samples
were incubated with anti-pERK (phosphoThr202/Tyr204)
(Cell Signaling, Danvers, MA), anti-CD31 (Abcam, Cam-
bridge, UK), and anti-CD4 and anti-CD8 (both from Cell
Signaling). Diaminobenzidine (3,30-diaminobenzidine) was
used as detection system (EnVisionþ System-HRP; Dako,
Santa Clara, CA). Morphometric quantification of the
percent area of liver vasculature (n ¼ 5 mice per treatment
arm) was performed by evaluating the mean area of CD31
staining in randomly selected low-magnification fields (n ¼
5, 10 fields for CD31 staining; n ¼ 10, 20 fields for
collagen) with ImageJ software.
RNA Extraction and Gene Expression Profiling of
Mice Livers
Total RNA from the 2 mouse models described was
extracted from 20 mg fresh-frozen nontumoral liver tissue
with Trizol reagent (Invitrogen, Waltham, MA) and purified
with RNeasy columns (Qiagen, Valencia, CA). RNA sample
concentration and quality were assessed by NanoDrop ND-
1000 spectrometer (NanoDrop, Wilmington, DE) and bio-
analyzer (Agilent, Palo Alto, CA), respectively. Gene
expression microarray studies were conducted using the
Gene Chip HT MG-430 (Affymetrix, Santa Clara, CA). The
raw .cel files were background corrected and normalized
with the robust multiarray averaging procedure,4 with a
custom chip definition file (.cdf) from the Custom CDF
project (HTMG430PM_Mm_ENTREZG v18.0).5 To assess
ICF-signature enrichment through ssGSEA (GenePattern),
mice genes were humanized, and intensity values were log
transformed. For quantitative reverse-transcription
polymerase chain reaction analysis, complementary DNA
was synthesized from 1 mg purified total RNA using Su-
perScript III reverse transcriptase (Invitrogen). Relative
gene expression levels were measured by TaqMan
Gene Expression Assays (Applied Biosystems, Foster City,
CA) by using specific probes for Col1a1 (Mm00801666_g1),
Col1a2 (Mm00483888_m1), Acta2 (Mm01546133_m1),
and Pdgfrb (Mm00435546_m1). The housekeeping gene
GAPDH (Mm99999915_g1) was used for normalization.
Microarray data of these newly profiled samples are in the
Gene Expression Omnibus under accession number
GSE125975.
Western Blot Analysis
Whole-cell extracts were collected in lysis buffer (50
mmol/L Tris pH 7.4, 150 mmol/L NaCl, 1% Triton X-100,
0.1% sodium dodecyl sulfate, 0.25 mmol/L EDTA, 1% so-
dium deoxycholate) containing phosphatases and proteases
inhibitors (Roche). Next, 30–70 mg of total protein were
resolved in polyacrylamide gels and transferred to nitro-
cellulose membranes (Pierce, Rockford, IL). Membranes
were blocked with bovine serum albumin and hybridized
overnight at 4C with primary antibodies against VEGFR-2,
pVEGFR-2 (Tyr951), Akt, pAkt (Ser473), ERK1/2, pERK1/2
(Thr202/Tyr204), Bcl-xL, PARP (all from Cell Signaling),
and tubulin (Sigma-Aldrich). Appropriate horseradish
peroxidase–conjugated secondary antibodies (Dako) were
incubated for 1 hour at room temperature, and immuno-
reactivity was detected with a LAS-3000 imaging system
(Fujifilm, Tokyo, Japan) by using Amersham ECL Prime
Western Blotting Detection Reagent (GE Healthcare,
Chicago, IL).
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Supplementary Figure 1. Identification of an ICF in the nontumor liver tissues and its association with overall survival in
patients with early HCC. (A) Consensus-clustered analysis of gene sets recapitulating the different cell states and perturba-
tions within the immune system. The figure includes a subgroup of representative gene sets among the approximately 5000
gene sets evaluated (Collection C7 of MsigDB). (B–D) Kaplan-Meier estimates of overall survival according to (B) the presence
of the ICF, (C) the presence of the high-infiltrate subtype, and (C) the different ICF subtypes. ns, not significant.
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Supplementary Figure 2. Immunohistochemistry assessment of CD4 and CD8 positivity in
nontumor liver tissues. Average stained area was automatically quantified and compared in (A)
samples from patients belonging to the ICF and non-ICF subgroups, and (B) between ICF
subtypes. n ¼ 15–19 samples per group. ***P < .001.
Supplementary Figure 3.Gene overlap
between the 172 ICF gene-expression
signature and other previously reported
poor-prognosis expression signatures in
nontumor liver tissue. Signatures are
denoted by the name of the first author
of each of the publications.6–10 Numbers
in brackets indicate the total number of
genes that constitute each signature,
and bold numbers represent the number
of genes that overlap between each
signature and the ICF signature (here,
referred to as Moeini).
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Supplementary Figure 4. External validation of the molecular and clinical features of the ICF and its subtypes. (A) The main
molecular characteristics of the ICF and the 3 distinct molecular subtypes were validated in a previously reported cohort that
included 225 FFPE nontumor liver tissue samples from patients with early HCC profiled by cDNA-mediated Annealing,
Selection, Extension, and Ligation (DASL) array. (B) Kaplan-Meier estimates of overall survival according to the presence of the
ICF. NTP, nearest template prediction.
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Supplementary Figure 5. Association of the presence of ICF subtypes with risk of HCC development and advanced liver
disease in patients with fibrosis. (A) Kaplan-Meier analysis of the correlation of the ICF subtypes with risk of HCC development.
(B) Correlation of the prediction of ICF subtypes with fibrosis and inflammation degree. Fibrosis degree was classified as none
(S0), low (S1/S2), and high (S3/S4). Inflammation degree was classified as none (G0), low (G1/G2), and high (G3/G4). Non ICF,
non-ICF subtype and unclassified cases; other ICF: high-infiltrate and proinflammatory ICFs.
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Supplementary
Figure 6. In silico enrich-
ment analysis of gene sets
recapitulating the targets
of approved molecular
therapies in nontumor liver
of patients with early HCC.
(A) Heatmap representing
the enrichment scores of
gene sets recapitulating
the molecular targets of
top enriched therapies in
nontumor liver of HCC pa-




enrichment of the gene set
of the main targets of top-
scored therapies centered
around the ICF phenotype.
The blue lines denote
presence of overlapping
genes among the different
gene sets. AUC.pval, area
under the curve P value;
NMI, normalized mutual
information; t.pval, t sta-
tistic P value; t.stat, t
statistic.
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Supplementary Figure 7. Prolonged treatment with nintedanib does not induce significant toxicity in DEN/CCl4-induced
mouse models. (A) Experimental design of the murine model of DEN/CCl4-induced hepatocarcinogenesis in the context of liver
fibrosis. (B) Monitoring of body weight in all mice from each experimental group during the administration of nintedanib or
vehicle at the longest time point, 18 weeks of age. (C) Evaluation of the serum levels of alanine transaminase (ALT) and
aspartate transaminase (AST) in each experimental group. Nin., nintedanib; Veh., vehicle.
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Supplementary Figure 8. Nintedanib inhibits the downstream mitogen-activated protein kinase pathway but has no effect on
reverting DEN/CCl4-induced platelet-derived growth factor signaling or hepatic fibrosis. (A) Western-blot analysis of down-
stream mitogen-activated protein kinase (protein kinase B and ERK) signaling. (B) Representative images and quantification of
pERK staining in 17-week-old mice treated with vehicle or nintedanib. In the vehicle arm, the tumors and adjacent nontumor
tissue are positive with patchy nuclear and cytoplasmic staining, whereas in the nintedanib arm, both are negative. (C) Western
blot analysis of the profibrogenic platelet-derived growth factor receptor signaling. (D) Representative images of Sirius Red
staining in mice treated with vehicle or nintedanib. Nintedanib did not exert any significant effect on liver fibrosis. (E) Gene
expression levels of profibrogenic marker genes by quantitative reverse-transcription polymerase chain reaction in livers of
mice killed at 15, 17, and 18 weeks of age treated with vehicle or nintedanib. The GAPDH gene was used as a housekeeper for
normalization. Significant statistical differences are defined as follows: *P < .05 and ***P < .001. Nin., nintedanib; NT, non-
tumor; T, tumor; Veh., vehicle.
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